Ole Andreas Halvorsen
Viking Global Investors
Ole Andreas Halvorsen Atea PharmaceuticalsInc stake
total: 670
Viking Global Investors AVIR trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2021 Q3
- Held for:
- 1 quarter
- Latest activity:
- 2021 Q4
According to 2026 Q2 report, Ole Andreas Halvorsen doesn't hold any Atea PharmaceuticalsInc (AVIR) shares. To date, the estimated cost basis is nearly $35.06 for "buy" trades and estimated average "sell" price is $35.06. Viking Global Investors first purchased AVIR in 2021 Q3, initially acquiring about 1.66M shares. Since the initial investment in Atea PharmaceuticalsInc (AVIR), Viking Global Investors has made 1 more transaction.
When did Ole Andreas Halvorsen sell Atea PharmaceuticalsInc (AVIR)?
Ole Andreas Halvorsen sold off the entire Atea PharmaceuticalsInc (AVIR) position in 2021 Q4.
When did Ole Andreas Halvorsen buy Atea PharmaceuticalsInc (AVIR)?
Ole Andreas Halvorsen first invested in Atea PharmaceuticalsInc (AVIR) in 2021 Q3 at the reported quarter-end price of $35.06 per share.
What's the cost basis of Viking Global Investors's AVIR stake?
The estimated cost basis for Atea PharmaceuticalsInc (AVIR) stake is around $35.06 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $35.06
- Weighted AVG sell price:
- $35.06
Ole Andreas Halvorsen's historical trades in Atea PharmaceuticalsInc
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q4
|
0.00%
|
0
|
$35.06
|
|
-100% (-1,655,087)
|
-0.16%
|
|
2021 Q3
|
0.16%
|
1,655,087
|
$35.06
|
$58,027,000
|
new
|
+0.16%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.